Ad
related to: astrazeneca lung cancer drugs list- Resources Info
Get Info on Resources
for a SCLC Treatment Option.
- Side Effects Info
Read on Potential Side Effects With
A SCLC Treatment Option.
- Dosing Info for Patients
Find Official Dosing Info & Related
Info for a SCLC Treatment Option.
- Learn About SCLC
Get Facts About SCLC & Learn About
A Treatment Option.
- Resources Info
Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration first approved the drug in 2017 to treat a type of bladder cancer. Imfinzi won approval for use in mid-stage non-small cell lung cancer a year later.
AstraZeneca's application was based on positive late-stage data that showed the drug improved overall survival and progression-free survival in patients with a type of lung cancer, whose disease ...
Monday, AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy ...
Pages in category "Drugs developed by AstraZeneca" The following 133 pages are in this category, out of 133 total. This list may not reflect recent changes. A.
On February 27, 2008, AstraZeneca announced that the use of cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was ...
AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not ...
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
The trial compared the two treatments -- AstraZeneca's drug and chemotherapy -- of patients whose non-small cell lung cancer had returned after one or two prior treatment attempts.
Ad
related to: astrazeneca lung cancer drugs list